We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App





First-of-Its-Kind Mobile Testing Platform Launched to Manage and Track On-Site COVID-19 Testing

By LabMedica International staff writers
Posted on 28 Aug 2020
Print article
Image: Fionet’s workflow (Photo courtesy of Fio Corporation)
Image: Fionet’s workflow (Photo courtesy of Fio Corporation)
A new first-of-its-kind COVID-19 mobile testing and tracking platform aims to enable lab-grade diagnostic testing in clinics, pharmacies, workplaces, airports, nursing homes and other community-based locations.

The new COVID-19 testing, data collection and reporting solution, Fionet, has been developed jointly by Relay Medical Corp. (Toronto, Canada) and Fio Corporation (Toronto, Canada). The Fionet mobile testing and tracking platform has been specifically developed for controlled, rapid response to pandemics. The platform combines handheld devices linked to online AI-powered cloud, automating frontline testing and capturing test results for tracking. Fionet’s rugged, mobile devices are compatible with multiple third-party antigen and antibody COVID-19 rapid diagnostic tests (RDTs), which creates sourcing flexibility for RDTs that are of limited supply and continuously evolving. Fionet also connects with molecular testing devices such as PCRs.

Flexible and customizable, Fionet enables testing to be expanded beyond the few overburdened medical centers to small clinics, pharmacies, workplaces, airports, nursing homes, schools, etc. and performed at hospital-grade accuracy, in higher volume, faster-speed, and by less-skilled frontline workers. Fionet has a proven, positive impact on one million patients with infectious diseases in over a dozen countries and four continents.

“Community-based testing and real-time tracking is indispensable for combating pandemics like COVID-19. Fionet has already made this happen in the most challenging epidemic regions on the planet and we are now preparing for imminent deployment of our platform with several partners to combat COVID-19 at home and abroad,” said Dr Michael Greenberg, CEO of Fionet Rapid Response Group, a joint venture set up by Relay Medical and Fio Corp.

“The many transformational benefits delivered by Fionet have been validated and documented in several dozen scientific and medical journals. Fionet has successfully reduced testing errors by 23%, achieves 99.5%1 diagnostic accuracy rate compared to expert lab techs, and provides significant economic efficiencies,” said Yoav Raiter, CEO, Relay Medical Corp.

Related Links:
Relay Medical Corp.
Fio Corporation



Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Photomicrograph of histology of a Ewing sarcoma in lung. The PAS stain highlights glycogen and the staining was negative with a PAS diastase stain (Photo courtesy of Nephron).

Comprehensive Molecular Profiling Matches Pediatric Patients to Therapies

A major challenge of using a comprehensive profiling approach for precision medicine is separating pathogenic from non-pathogenic molecular changes within a tumor. A program has been presented of the... Read more

Industry News

view channel
Image: Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually (Photo courtesy of Mindray)

Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually

High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.